, Volume 114, Issue 4, pp 559–565 | Cite as

Binding of antidepressants to human brain receptors: focus on newer generation compounds

  • Bernadette Cusack
  • Albert Nelson
  • Elliott Richelson
Original Investigations


Using radioligand binding assays and postmortem normal human brain tissue, we obtained equilibrium dissociation constants (Kds) for 17 antidepressants and two of their metabolites at histamine H1, muscarinic, α1-adrenergic, α2-adrenergic, dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2 receptors. Several newer antidepressants were compared with older drugs. In addition, we studied some antimuscarinic, antiparkinson, antihistamine, and neuroleptic compounds at some of these receptors. For the antidepressants, classical tricyclic antidepressants were the most potent drugs at five of the seven receptors (all but α2-adrenergic and 5-HT1A receptors). The chlorophenylpiperazine derivative antidepressants (etoperidone, nefazodone, trazodone) were the most potent antidepressants at α2-adrenergic and 5-HT1A receptors. Of ten antihistamines tested, none was more potent than doxepin at histamine H1 receptors. At muscarinic receptors antidepressants and antihistamines had a range of potencies, which were mostly weaker than those for antimuscarinics. From the in vitro data, we expect adinazolam, bupropion, fluoxetine, sertraline, tomoxetine, and venlafaxine not to block any of these five receptors in vivo. An antidepressant's potency for blocking a specific receptor is predictive of certain side effects and drug-drug interactions. These studies can provide guidelines for the clinician in the choice of antidepressant.

Key words

Histamine H1 receptor Muscarinic receptor α1-adrenoceptor, α2-adrenoceptor Dopamine D2 receptor Serotonin 5-HT1A receptor Serotonin 5-HT2 receptor Antihistamines Antimuscarinics Neuroleptics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576–580Google Scholar
  2. Bolden-Watson C, Richelson E (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023–1029Google Scholar
  3. Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989) Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35:469–476Google Scholar
  4. Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney JW (1992) Pharmacological characteristics of α2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol 42:1–5Google Scholar
  5. Convents A, De Keyser J, De Backer JP, Vauquelin G (1989) [3H]Rauwolscine labels α2-adrenoceptors and 5-HT1A receptors in human cerebral cortex. Eur J Pharmacol 159:307–310Google Scholar
  6. Cusack BM, Richelson E (1993) A method for radioligand binding assays using a robotic workstation. J Recept Res 13[1–4]: 123–134Google Scholar
  7. De Lean A, Hancock AA, Lefkowitz RJ (1982) Validation and statistical analysis of a computer modelling method for quantitative analysis of radio-ligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21:5–16Google Scholar
  8. De Vos H, Czerwiec E, De Backer JP, De Potter W, Vauquelin (1991) [3H]Rauwolscine behaves as an agonist for the 5-HT1A receptors in human frontal cortex membranes. Eur J Pharmacol 207:1–8Google Scholar
  9. Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M (1991) Trimipramine — an atypical neuroleptic? Int Clin Psychopharmacol 6:147–153Google Scholar
  10. Fleming WW, Westfall DP, De La Landi LS, Jellet LB (1972) Lognormal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther 181:339–345Google Scholar
  11. Fuller RW, Snoddy HD, Cohen ML (1984) Interactions of trazodone with serotonin neurons and receptors. Neuropharmacology 23:539–544Google Scholar
  12. Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: [3H]-PAT. Nature 305:140–142Google Scholar
  13. Kanba S, Richelson E (1984) Histamine H1 receptors in human brain labeled with [3H]doxepin. Brain Res 304:1–7Google Scholar
  14. Morrow AL, Creese I (1986) Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol Pharmacol 29:321–330Google Scholar
  15. Munson PJ, Rodbard D (1980) LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239Google Scholar
  16. Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47[2]: 529–540Google Scholar
  17. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil T, M., LaPierre YD, Masco HL, Mendels J (1991) Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51:18–27Google Scholar
  18. Richelson E (1993) Review of Antidepressants in the treatment of mood disorders. In: Dunner DL (ed) Current psychiatric therapy. Saunders, Philadelphia, pp 232–239Google Scholar
  19. Richelson E, Nelson A (1984a) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94–102Google Scholar
  20. Richelson E, Nelson A (1984b) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197–204Google Scholar
  21. Smith WT, Glaudin V (1992) A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin, Psychiatry 53:36–39Google Scholar
  22. Stanton TT, Bolden-Watson C, Cusack B, Richelson E (1993) Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 45:2352–2354Google Scholar
  23. Wander TJ, Nelson A, Okazaki H, Richelson E (1986) Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol 132:115–121Google Scholar
  24. Wander TJ, Nelson A, Okazaki H, Richelson E (1987) Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2A receptors of normal human brian in vitro. Eur J Pharmacol 143:279–282Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Bernadette Cusack
    • 1
  • Albert Nelson
    • 2
  • Elliott Richelson
    • 1
  1. 1.Department of ResearchMayo Clinic JacksonvilleJacksonvilleUSA
  2. 2.Department of PharmacologyMayo Foundation and Mayo ClinicRochesterUSA

Personalised recommendations